All In MedTech

Device Trial Radar · NCT04025762

24/7 Closed-loop in Older Subjects With Type 1 Diabetes

An Open-label, Multi-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of 16 Week Day and Night Automated Closed-loop Glucose Control Under Free Living Conditions Compared to Sensor Augmented Insulin Pump Therapy in Older Adults With Type 1 Diabetes.

Last checked: Nov 19, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Sep 1, 2019

Primary completion

Aug 20, 2021

Study completion Aug 20, 2021

Sponsor

Lead sponsor
University of CambridgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Manchester University NHS Foundation Trust; University Hospital Birmingham NHS Foundation Trust; Medical University of Graz
First posted
Jul 19, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this open-label, multi-centre, randomised, crossover design study is to determine whether automated day and night closed-loop insulin delivery for 16 weeks under free living conditions is safer and more efficacious compared to sensor augmented insulin pump therapy in older adults with type 1 diabetes. The primary outcome is time spent in target range between 3.9 and 10.0 mmol/L (70 and 180 mg/dl) as recorded by CGM. Secondary outcomes are the HbA1c, time spent with glucose levels above and below target, as recorded by CGM, and other CGM-based metrics. Measures of human factor assessments, cardiac arrhythmias and objective sleep quality assessment will also be evaluated in this study.

Conditions

  • Type 1 Diabetes Mellitus
  • Hypoglycemia
  • Arrythmia

Interventions

  • Hybrid closed-loop system (CamAPS FX)Device

    Hybrid closed-loop system

  • Sensor augmented pump therapyDevice

    Sensor augmented pump therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Time Spent in the Target Sensor Glucose Range During the 16 Week Intervention Period (%)Time frame: 16 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Manchester Royal Infirmary

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.